Advances of ceftazidime/avibactam in the treatment of carbapenem-resis-tant Klebsiella pneumoniae infection
10.12138/j.issn.1671-9638.20245118
- VernacularTitle:头孢他啶/阿维巴坦治疗耐碳青霉烯类肺炎克雷伯菌感染的研究进展
- Author:
Yuan-Qi ZHAO
1
;
Ming-Jing CHENG
;
Miao-Miao XIONG
;
Min XIAO
;
Xiu-Yu CUI
;
Zi-Jian ZHOU
;
Yi-Wei YU
;
Wei-Dong ZHAO
Author Information
1. 大理大学临床医学院,云南大理 671000
- Keywords:
ceftazidime/avibactam;
Klebsiella pneumoniae;
carbapenemase;
carbapenem-resistant Klebsiella pneumoniae
- From:
Chinese Journal of Infection Control
2024;23(8):1047-1052
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,the prevalence of carbapenem-resistant Klebsiella pneumoniae(CRKP)infection has become a global public health issue.Ceftazidime/avibactam(CAZ/AVI)has been approved as a novel antimicrobial agent for the treatment of healthcare-associated pneumonia/ventilator-associated pneumonia,bloodstream infection,infection after kidney transplantation,and severe infection combined with liver cirrhosis.However,the use of CAZ/AVI has also led to the emergence of drug-resistant strains.The major mechanisms of drug-resistance include over-expression of blaKPC gene,mutation of β-lactamase and amino acids at key sites,changes in cell permeability caused by loss of membrane porin,and over-expression of efflux pump.This article reviews the research progress of CAZ/AVI in the treatment of CRKP infection,providing reference for clinical diagnosis and treatment.
